Global Neurodiagnostics Market - 2025-2033

The global neurodiagnostics market size reached US$ 9.35 billion in 2024 and is expected to reach US$ 21.17 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025-2033.

Neurodiagnostics refers to a specialized branch of medical diagnostics that focuses on the identification, monitoring, and evaluation of neurological disorders through the use of various diagnostic techniques and tools. These techniques are primarily designed to assess the function, structure, and overall health of the nervous system, including the brain, spinal cord, and peripheral nerves.

Neurodiagnostics encompasses both electrophysiological and imaging-based tests, as well as molecular diagnostics in some cases, to assist healthcare providers in diagnosing conditions related to the central and peripheral nervous systems. These conditions include neurological diseases such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain tumors, traumatic brain injuries (TBI), and sleep disorders, among others.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neurodiagnostics are significantly driving the neurodiagnostics market growth.

Rising technological advancements are significantly driving the growth of the neurodiagnostics market by enabling early diagnosis, improving accuracy, enhancing patient outcomes, and expanding accessibility to diagnostic tools. These innovations are also leading to cost-effective solutions, improved patient care, and the development of personalized treatment plans for neurological diseases. Thus, the key and emerging market players are focusing on technologically advanced neurodiagnostics, which are further boosting the growth of the market

For instance, in April 2025, Neurodiagnostics developer Cadwell Industries launched its latest Sierra software release, providing patent-pending, synchronized ultrasound and electromyography (EMG). Combined with the Sierra Summit electrodiagnostic system and Sierra NMUS1 integrated ultrasound, the update brings electrophysiological data and ultrasound imaging together in real time on a single screen. This aims to assist in needle EMG, chemodenervation, nerve block, and hydrodissection procedures.

Additionally, in August 2024, Natus Medical Incorporated launched autoSCORE, the first-of-its-kind artificial intelligence model capable of automatic and comprehensive clinical EEG interpretation, providing accuracy on par with medical experts. The autoSCORE application has the potential to improve clinical outcomes and the value of care for the millions suffering from epilepsy.

High cost of neurodiagnostic procedures hampering the market growth

The high costs associated with neurodiagnostic procedures represent a significant barrier to market growth, limiting access to advanced diagnostic tools, especially in low-income regions and for underinsured patients. These costs hinder the widespread adoption of cutting-edge neurodiagnostic technologies, delaying diagnosis and treatment for many individuals with neurological conditions.

Many of the advanced neurodiagnostic technologies, such as EEG, MRI, CT scans, and PET scans, require expensive equipment and maintenance, making them difficult for smaller hospitals or clinics to afford. In addition to the costs of equipment, the procedures themselves can be financially burdensome for patients, particularly for those requiring regular diagnostic tests such as EEG, MRI, and CT scans. For instance, video EEG monitoring costs an average of $77,664 before insurance.

As the neurodiagnostics market continues to expand, addressing these cost challenges will be crucial for improving accessibility and affordability. Solutions like cost-effective diagnostic tools, insurance reforms, and government funding for advanced neurodiagnostic technologies are essential to overcome these barriers and drive market growth in the coming years.

Segment Analysis

The global neurodiagnostics market is segmented based on product type, application, end-user, and region.

Product Type:

The diagnostic equipment segment is expected to dominate the neurodiagnostics market with the highest market share.

The diagnostic equipment segment is the dominant segment in the neurodiagnostics market due to its crucial role in early detection, accurate diagnosis, and monitoring of neurological diseases. Technologies such as MRI, CT scans, EEG, and PET scans are essential tools for clinicians in diagnosing neurological disorders, including stroke, Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors.

The continued development of advanced imaging systems and non-invasive diagnostic tools has solidified the diagnostic equipment segment as the leading contributor to the market. Moreover, the novel product launches by key and emerging players by regulatory support are also boosting the segment growth.

For instance, in October 2024, Natus Medical Incorporated submitted an FDA 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Natus point-of-care EEG device. The rapid-deploy decision-support tool is designed to quickly help identify non-convulsive seizures (NCSs) and status epilepticus in acute care environments, supporting rapid intervention and streamlining treatment decisions to improve patient outcomes.

This point-of-care EEG system leverages Natus's leading NeuroWorks software platform to provide a seamless and familiar review experience with remote neurologist collaboration, 24/7 from any web browser. NeuroWorks EEG systems are trusted by more health systems and small practices around the world. With its unparalleled expertise in complex IT environments, Natus will utilize a leading cybersecurity-certified cloud platform to ensure patient data security.

Geographical Analysis

North America is expected to hold a significant position in the global neurodiagnostics market with the highest market share

The North America region is the dominant market for neurodiagnostics, driven by factors such as advanced healthcare infrastructure, high healthcare spending, widespread access to cutting-edge neurodiagnostic technologies, and a high prevalence of neurological diseases. This dominance is also supported by the presence of leading healthcare providers, manufacturers of diagnostic equipment, and ongoing advancements in research and development (R&D).

According to the Alzheimer's Association, nearly 7 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. This rising incidence of neurological disorders in North America, including Alzheimer's disease, Parkinson's disease, stroke, epilepsy, and multiple sclerosis, is a significant factor propelling the growth of the neurodiagnostics market. As the prevalence of neurological conditions is increasing, there is a greater need for accurate diagnostic tools.

North America is at the forefront of technological innovation in the neurodiagnostics market, with continuous advancements in diagnostic tools that improve both the accuracy and efficiency of neurological diagnoses. These innovations include AI-powered diagnostic tools and wearable EEG devices, which are transforming how neurological conditions are diagnosed and managed.

For instance, in November 2024, LVIS Corporation launched NeuroMatch Access, an artificial-intelligence (AI)-driven platform for electroencephalogram (EEG) data analysis in the US. The Silicon Valley, US-based company's platform, which received 510(k) clearance from the US Food and Drug Administration (FDA) in May 2023, uses AI to review and interpret EEG signals by removing unwanted artifacts. EEG is used to measure the electrical activity of the brain and can aid in the diagnosis of conditions, including brain damage and epilepsy.

Competitive Landscape

Top companies in the neurodiagnostics market include GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., FUJIFILM Holdings, Thermo Fisher Scientific Inc., Compumedics Limited, Natus, Stratus, Canon Medical Systems USA, Inc., Nihon Kohden Corporation, and among others.

Key Developments

• In April 2025, Cadwell Industries launched its latest Sierra software release, providing patent-pending, synchronized ultrasound and electromyography (EMG). Combined with the Sierra Summit electrodiagnostic system and Sierra NMUS1 integrated ultrasound, the update brings electrophysiological data and ultrasound imaging together in real time on a single screen. This aims to assist in needle EMG, chemodenervation, nerve block, and hydrodissection procedures.
• In October 2023, Ceribell, Inc. announced the commercial release of its new AI algorithm, ClarityPro, accompanying the availability of potential additional reimbursement for eligible Medicare patients. ClarityPro is an AI-based software algorithm within the Ceribell EEG system that analyzes EEG waveforms to diagnose electrographic status epilepticus (ESE).
• In October 2023, BeCareLink introduced a new quantitative and artificial intelligence (AI)-enabled app called BeCare Neuro Link, the new mobile application is intended for the remote, objective, and comprehensive assessment of neurologic patients or those with potential neurologic conditions. It can be used for screening as-of-yet-undiagnosed neurologic conditions as well as monitoring the response to treatment for known neurologic disorders.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurodiagnostics market report delivers a detailed analysis with 62 key tables, more than 61 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.